Company News-Bio-Thera Solutions, Ltd.

2026-05-18

GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline...

查看详情

11-292023

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara®

Theclinical comparative study met its primary endpoint and showed similar efficacyand comparable safety profile in patie...
10-252023

Bio-Thera Solutions Announces GMP Approval from ANVISA

GUANGZHOU,China, October 24, 2023 -- Bio-Thera Solutions, Ltd (688177:SH), acommercial-stage biopharmaceutical company d...
10-082023

FDA Approves TOFIDENCE® (tocilizumab-bavi) a Biosimilar of ACTEMRA® developed by Bio-Thera Solutions

TOFIDENCE is Bio-Thera’s first productapproved by USFDA.TOFIDENCE is the first monoclonal antibodydrug researched, devel...